Overview

Efficacy of Aprepitant (Emend®) in Children

Status:
Completed
Trial end date:
2017-06-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether or not adding aprepitant(Emend®) to the standard therapy will help children who receive chemotherapy to have less nausea and vomiting.
Phase:
Phase 3
Details
Lead Sponsor:
University of Oklahoma
Treatments:
Antiemetics
Aprepitant
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Fosaprepitant
Ondansetron